Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Krystal Biotech (KRYS)

Krystal Biotech: Chief Commercial Officer Andrew Orth resigns, last day August 2, 2023

Neutral Impact 3 of 5 leadership Written later

Krystal Biotech disclosed that Andrew Orth, its Chief Commercial Officer, resigned and that his last day with the company was August 2, 2023. The filing does not give a reason for the departure or name a successor, and it does not describe any financial impact.

Key points

  • Andrew Orth, Chief Commercial Officer, resigned from his position.
  • Orth's last day with Krystal Biotech was August 2, 2023.
  • The filing does not name a replacement or state a reason for the resignation.

The filing

CompanyKrystal Biotech (KRYS)
Form8-K, current report
Filed with the SECAug 7, 2023, 8:18 AM ET
Accession number0001711279-23-000069

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:17 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 07, 2023.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.